Arovella Therapeutics (ASX:ALA) has reported new preclinical data that strengthens the case for its engineered immune cell platform, demonstrating sustained and enhanced killing of pancreatic and gastric cancer cells in laboratory studies.
At the centre of the work is a modified immune cell, an invariant natural killer T cell (iNKT cell), engineered to express a chimeric antigen receptor targeting claudin 18.2. This protein is an increasingly important therapeutic target because it is commonly exposed on the surface of cancer cells in gastric and pancreatic tumours while remaining largely inaccessible in healthy tissue.
In controlled in vitro experiments, these CLDN18.2-targeting CAR-iNKT cells demonstrated potent cytotoxic activity, effectively eliminating cancer cells expressing the target antigen. When researchers repeatedly reintroduced tumour cells across multiple cycles designed to simulate ongoing disease pressure, the engineered cells maintained strong tumour control, highlighting their persistence and resilience under stress.
The most notable gains came with the addition of IL-12-TM armouring, a modification that enhances immune cell function. Armoured CAR-iNKT cells showed greater expansion and sustained killing capacity across successive tumour challenges.
According to the data, these enhanced cells eliminated more than 97 per cent of pancreatic cancer cells and over 80 per cent of gastric cancer cells, even after repeated exposures, a level of endurance that suggests meaningful therapeutic potential.
The visual data presented in the charts on page 2 reinforce this performance gap. The graphs illustrate that while non-armoured CAR-iNKT cells lose effectiveness after multiple tumour challenges, the IL-12-TM armoured cells maintain near-maximal cytotoxicity and continue to proliferate, indicating both functional persistence and biological expansion.
In healthy gastric tissue, claudin 18.2 is hidden within tight junctions between cells. As malignancy develops, the protein becomes exposed and accessible, allowing engineered immune cells to recognise and attack tumour cells with specificity. This selective targeting is particularly relevant given the high proportion of gastric and pancreatic cancers that express CLDN18.2, including many cases that lack other actionable biomarkers.
Solid tumours have remained a major hurdle for cell therapy due to issues such as poor persistence, limited infiltration, and immune suppression within the tumour microenvironment. By combining targeted CAR design with cytokine armouring, Arovella’s platform appears to enhance both the potency and durability of the immune response, two critical parameters for clinical success.
Company leadership views the results as a validation of both the targeting strategy and the armouring technology. The next phase of development will move beyond in vitro systems into animal models, where the therapy’s performance in more complex biological environments will be assessed.